---
title: "Neurocrine Biosciences Executives and Director Sell Shares"
date: "2025-02-13 08:00:00"
summary: "Reporter NameRelationshipTypeAmountSEC FilingAbernethy MattChief Financial OfficerSell$115,908Form 4Benevich EricChief Commercial OfficerSell$115,940Form 4Boyer David W.Chief Corp. Affairs OfficerSell$82,820Form 4Gano KyleChief Executive OfficerSell$116,020Form 4Several executives at Neurocrine Biosciences have recently sold shares of the company's common stock. Matt Abernethy, the Chief Financial Officer, sold 980 shares at a weighted average price of $118.274..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

| Reporter Name | Relationship | Type | Amount | SEC Filing |
| --- | --- | --- | --- | --- |
| Abernethy Matt | Chief Financial Officer | Sell | $115,908 | [Form 4](https://www.sec.gov/Archives/edgar/data/1724097/000091447525000046/xslF345X05/wk-form4_1739403711.xml) |
| Benevich Eric | Chief Commercial Officer | Sell | $115,940 | [Form 4](https://www.sec.gov/Archives/edgar/data/1643653/000091447525000047/xslF345X05/wk-form4_1739403854.xml) |
| Boyer David W. | Chief Corp. Affairs Officer | Sell | $82,820 | [Form 4](https://www.sec.gov/Archives/edgar/data/1909817/000091447525000048/xslF345X05/wk-form4_1739403976.xml) |
| Gano Kyle | Chief Executive Officer | Sell | $116,020 | [Form 4](https://www.sec.gov/Archives/edgar/data/1567160/000091447525000049/xslF345X05/wk-form4_1739404081.xml) |

Several executives at Neurocrine Biosciences have recently sold shares of the company's common stock. Matt Abernethy, the Chief Financial Officer, sold 980 shares at a weighted average price of $118.274 each, totaling $115,908. Following this transaction, Abernethy now directly owns 33,561 shares.

Eric Benevich, the Chief Commercial Officer, also sold 980 shares, but at a slightly higher weighted average price of $118.3065 each, for a total of $115,940. Post-sale, Benevich's direct ownership stands at 42,799 shares.

David W. Boyer, the Chief Corporate Affairs Officer, sold 700 shares at a weighted average price of $118.3144 each, totaling $82,820. After the sale, Boyer directly owns 1,998 shares.

Gano Kyle, the Chief Executive Officer, sold 980 shares at a weighted average price of $118.3881 each, with the total amounting to $116,020. Kyle's direct ownership after the transaction is 137,658 shares.

[TradingView](https://www.tradingview.com/news/tradingview:6e8281721a81f:0-neurocrine-biosciences-executives-and-director-sell-shares/)
